Antisense Oligonucleotides Modulating CFTR Splicing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cystic fibrosis (CF) are inadequate, as they do not effectively address the underlying genetic mutations that lead to the disease, resulting in persistent lung infections and other organ damage.
Innovation Solution
The use of antisense oligonucleotides (ASOs) that specifically target and modify the splicing of CFTR gene transcripts, leading to the production of functional CFTR protein by skipping mutated exons and restoring the open reading frame.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments (antibiotics, inhalation therapies) are used for cystic fibrosis, then lung infections are treated and symptoms are managed, but the underlying genetic mutations are not addressed and the disease progresses
Solution Approach 1:
Antisense oligonucleotides serve as intermediary molecules that bridge the gap between the mutated CFTR gene and functional protein production. These ASOs bind to specific sequences in the CFTR pre-mRNA to modulate splicing, acting as a mediator that corrects the genetic defect at the RNA level rather than requiring direct gene editing or protein replacement
Solution Approach 2:
The treatment applies preliminary action by correcting the splicing defect at the RNA level before protein synthesis occurs. By modifying pre-mRNA splicing patterns in advance, the therapy ensures that functional CFTR protein is produced from the outset, preventing the accumulation of defective proteins and downstream pathological effects
2Reliability
If antisense oligonucleotides target CFTR transcripts to restore protein function, then functional CFTR protein is produced at the plasma membrane, but the complexity of the molecular mechanism increases
Solution Approach 1:
The invention replaces complex mechanical or surgical interventions with a molecular-level chemical mechanism. Instead of physical procedures, the therapy uses antisense oligonucleotides that exploit natural RNA-protein interactions and splicing machinery to achieve therapeutic effects, substituting mechanical complexity with biochemical specificity
Solution Approach 2:
The treatment changes key parameters of the CFTR gene expression system by modifying splicing patterns. By altering which exons are included or excluded in the mature mRNA, the therapy changes the structural and functional parameters of the resulting protein, transforming a non-functional transcript into a functional one through parameter modification rather than system redesign
3Ease of operation
If current therapies are used, then treatment can be administered, but the disease continues to progress with persistent infections and organ damage
Solution Approach 1:
The antisense oligonucleotide therapy performs preliminary action by addressing the root genetic cause of the disease before pathological processes fully develop. By correcting splicing defects at the RNA level, the treatment prevents the formation of defective proteins that would otherwise lead to persistent infections and progressive organ damage, acting preemptively rather than reactively
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach results in increased levels of correctly localized and functional CFTR protein at the plasma membrane, potentially leading to improved lung function and reduced symptoms in CF patients.
Implementation Method 1
compounds comprising oligonucleotides complementary to a cystic fibrosis transmembrane conductance regulator (CFTR) RNA transcript. Certain such compounds are useful for hybridizing to a CFTR transcript
Data Source
AI summary
The present disclosure relates generally to compounds comprising oligonucleotides complementary to a cystic fibrosis transmembrane conductance regulator (CFTR) RNA transcript. Certain such compounds are useful for hybridizing to a CFTR RNA transcript, including but not limited to a CFTR RNA transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing and/or expression of the CFTR transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with Cystic Fibrosis.